Avec la nouvelle réglementation ICH Q3D, le contrôle des impuretés élémentaires dans les produits pharmaceutiques a pris une nouvelle dimension de par son impact sur la libération du produit fini et son application aux produits déjà commercialisés.
This document provides guidelines for assessing and controlling elemental impurities in drug products. It establishes permitted daily exposure (PDE) levels for various elemental impurities based on toxicity data. It then describes a risk-based approach to control elemental impurities in drug products by identifying potential sources, evaluating risks, and defining necessary controls. The guidelines apply to new drug products and do not expect existing products to tighten limits unless exceeding PDEs.
ICH Q6A Specifications by Chandra MohanChandra Mohan
The document provides guidelines on specifications for new drug substances and products. It defines specifications and outlines universal tests that should be included for both drug substances and products, such as description, identification, assay, and impurities. It also describes specific tests that may be included depending on the dosage form, such as dissolution, disintegration, hardness/friability for solid oral dosage forms. The guidelines provide information on justifying acceptance criteria and setting specifications based on development data and stability studies.
CCK Discussion Forum on Impurity Emergence: A Wake Up Call for Drug Safety & Quality - 13 Oct 2019 at ICCBS, University of Karachi. Session largely participated by qualified and experienced pharmaceutical professionals having diversified educational background and experience.
Reference standards in Pharmaceutical Industriesbhavanavedantam
This presentation is brief introduction about reference standards that are using in pharmaceutical industries for calibration of different instruments, methods and pharmaceutical chemicals...
The document provides guidelines for specifications of new drug substances and products. It discusses setting specifications based on development data and stability studies. Universal tests for drug substances include identification, assay, impurities. For products, additional tests depend on dosage form and may include dissolution, uniformity, sterility. The guidelines provide concepts for justifying specifications and periodic testing. They apply principles for biotech products, addressing characterization, analytical validation, process controls, and linking specifications to manufacturing and clinical data.
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s).
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s)
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s)
Q1E Evaluation of Stability Data by Rahim Khoja presented on December 22, 2014Rahim Khoja
This document provides guidelines for using stability data to propose a retest period or shelf life in product registration. It describes how extrapolation of data beyond the available long-term data can be considered. The guidelines recommend a systematic approach to presenting and evaluating stability data from physical, chemical, biological and microbiological tests. Extrapolation may be proposed if no significant changes are observed under accelerated conditions and it is assumed the same change pattern will continue. A retest period granted via extrapolation should be verified with additional long-term data. The guidelines also provide decision trees and examples of statistical analyses to determine if data from different batches can be pooled for evaluating a single proposed period.
A detailed look at impurities in medicinesTGA Australia
This document provides a detailed look at impurities in medicines through a presentation given by Dr. John Churchill. It discusses major topics like the identification and limits of impurities in drug substances and products. Specific examples are given to illustrate issues like inorganic impurities, residual solvents, genotoxic impurities, and cases where impurities have caused adverse reactions. Guidelines for setting specifications and limits from organizations like ICH and TGA are also summarized. The presentation examines challenges in qualifying, detecting, and controlling impurities to ensure the quality, safety and effectiveness of medicines.
This document provides guidelines for assessing and controlling elemental impurities in drug products. It establishes permitted daily exposure (PDE) levels for various elemental impurities based on toxicity data. It then describes a risk-based approach to control elemental impurities in drug products by identifying potential sources, evaluating risks, and defining necessary controls. The guidelines apply to new drug products and do not expect existing products to tighten limits unless exceeding PDEs.
ICH Q6A Specifications by Chandra MohanChandra Mohan
The document provides guidelines on specifications for new drug substances and products. It defines specifications and outlines universal tests that should be included for both drug substances and products, such as description, identification, assay, and impurities. It also describes specific tests that may be included depending on the dosage form, such as dissolution, disintegration, hardness/friability for solid oral dosage forms. The guidelines provide information on justifying acceptance criteria and setting specifications based on development data and stability studies.
CCK Discussion Forum on Impurity Emergence: A Wake Up Call for Drug Safety & Quality - 13 Oct 2019 at ICCBS, University of Karachi. Session largely participated by qualified and experienced pharmaceutical professionals having diversified educational background and experience.
Reference standards in Pharmaceutical Industriesbhavanavedantam
This presentation is brief introduction about reference standards that are using in pharmaceutical industries for calibration of different instruments, methods and pharmaceutical chemicals...
The document provides guidelines for specifications of new drug substances and products. It discusses setting specifications based on development data and stability studies. Universal tests for drug substances include identification, assay, impurities. For products, additional tests depend on dosage form and may include dissolution, uniformity, sterility. The guidelines provide concepts for justifying specifications and periodic testing. They apply principles for biotech products, addressing characterization, analytical validation, process controls, and linking specifications to manufacturing and clinical data.
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s).
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s)
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s)
Q1E Evaluation of Stability Data by Rahim Khoja presented on December 22, 2014Rahim Khoja
This document provides guidelines for using stability data to propose a retest period or shelf life in product registration. It describes how extrapolation of data beyond the available long-term data can be considered. The guidelines recommend a systematic approach to presenting and evaluating stability data from physical, chemical, biological and microbiological tests. Extrapolation may be proposed if no significant changes are observed under accelerated conditions and it is assumed the same change pattern will continue. A retest period granted via extrapolation should be verified with additional long-term data. The guidelines also provide decision trees and examples of statistical analyses to determine if data from different batches can be pooled for evaluating a single proposed period.
A detailed look at impurities in medicinesTGA Australia
This document provides a detailed look at impurities in medicines through a presentation given by Dr. John Churchill. It discusses major topics like the identification and limits of impurities in drug substances and products. Specific examples are given to illustrate issues like inorganic impurities, residual solvents, genotoxic impurities, and cases where impurities have caused adverse reactions. Guidelines for setting specifications and limits from organizations like ICH and TGA are also summarized. The presentation examines challenges in qualifying, detecting, and controlling impurities to ensure the quality, safety and effectiveness of medicines.
This document provides information about nitrosamine impurities found in angiotensin II receptor blockers (ARBs) like valsartan, losartan, and irbesartan. It discusses how various nitrosamine impurities like NDMA, NDEA, and NMBA were discovered in 2018-2019 through recalls of ARB medications from multiple manufacturers. It outlines the global investigations and testing methods developed by regulatory agencies like the FDA to detect these genotoxic and carcinogenic impurities and ensure the safety of the drug supply.
The document discusses the International Conference on Harmonization (ICH), which aims to harmonize technical requirements for pharmaceutical registration across Europe, Japan, and the United States. It was established in 1990 as a tripartite effort between regulatory authorities and the research-based pharmaceutical industry. The ICH seeks to reduce unnecessary delay in global drug development by achieving greater harmonization and applying technical guidelines consistently. This will help ensure safe, effective, and high quality new medicines are available more efficiently.
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSBhaumik Bavishi
The document provides guidelines for submitting stability data for drug substances and drug products as part of a registration application. It outlines the objectives, scope, and general principles of stability testing. Guidelines are given for conducting long-term, accelerated, and intermediate stability studies under various storage conditions. Specifications, testing frequency, number of batches, and container closure systems are also addressed. A commitment to continuing stability studies is recommended if the available data does not cover the proposed shelf life period.
This document discusses the requirements for regulatory submissions for marketing authorization in various countries and regions.
It provides an overview of the key documents needed for marketing authorization in India, including application forms, manufacturing licenses, site documents, and product information.
It also summarizes the common ICH CTD format used for submissions to countries like the EU, US, and Japan, as well as the ASEAN CTD format used in Southeast Asian countries. The ASEAN CTD and ICH CTD formats are compared, highlighting similarities and differences in their organization.
Finally, specific documentation requirements are outlined for dossier submissions in countries like Myanmar, Vietnam, and Singapore, focusing on drug substance specifications, analytical methods, and
Impurities in drug substance (ich q3 a)Bhanu Chava
This document discusses guidelines for classifying, reporting, controlling, and qualifying impurities in new drug substances. It defines types of impurities and provides thresholds for reporting, identifying, and qualifying impurities. The key points are:
- Impurities are classified as organic, inorganic, or residual solvents. Organic impurities can arise from starting materials, byproducts, or degradation.
- Identification thresholds determine which impurities must be identified and qualified. Impurities above reporting thresholds must be reported.
- Specifications list individual specified impurities and general limits for unspecified impurities.
- Qualification involves evaluating safety data for impurities at specified levels. Impurities may need further study if usual qualification thresholds
The document discusses guidelines for controlling elemental impurities in pharmaceutical products according to ICH Q3D. It provides information on:
- Common sources of elemental impurities in drug products
- Classification of elements into categories based on their toxicity and likelihood of occurrence
- Methods for establishing permitted daily exposures (PDEs) for elements
- A risk-based approach to assessing and controlling elemental impurities that includes identifying potential sources, evaluating levels compared to PDEs, and documenting control plans
- Options for converting PDEs into concentration limits in drug products or components
The guidelines aim to replace qualitative heavy metal limits with quantitative control of specific elemental impurities shown to have no therapeutic benefit. Manufacturers must
This document provides a summary of the key steps to implement ICH Q3D Guideline for Elemental Impurities:
1. Collect baseline information on potential elemental impurity sources from suppliers.
2. Define the risk assessment strategy to use, such as the component-based Options 1, 2A, 2B or finished-product Option 3.
3. Develop an analytical plan using techniques like ICP-MS to test for elemental impurities.
4. Establish a control strategy where impurities below 30% of the PDE are acceptable.
5. Manage the implementation as a continuous process, reassessing for product or supplier changes.
A comprehensive description of the new requirements introduced by ISO 14971:2019 Application of risk management to medical devices and ISO/TR 24971 Technical Report for the FDA, MDR and IVDR
The document discusses the Paediatric Committee (PDCO) at the European Medicines Agency and its role in regulating medicines for children. It describes how prior to 2007, 50-90% of paediatric medicines lacked testing and evaluation. The Paediatric Regulation of 2007 established the PDCO and incentives like extended exclusivity periods to stimulate research into paediatric medicines. The key tools are Paediatric Investigation Plans which must be approved by the PDCO and outline a medicine's paediatric development. The regulation aims to improve children's health through ethical research while not delaying adult approvals. However, its translation into health benefits requires transparency and coordination between regulators and industry.
The document discusses ICH stability guidelines for pharmaceutical products. It provides an overview of key ICH guidelines including Q1A(R2) on stability testing of new drug substances and products and Q1B on photo stability testing. Q1A(R2) outlines the core stability data package required, including testing conditions, number of batches, and stability commitments. It also defines criteria for significant changes. Q1B covers photo stability testing conditions and study design. The guidelines aim to provide stability information for marketing applications and ensure quality, safety and efficacy over the shelf life of pharmaceutical products.
Best techniques to control Genotoxities and impact of ICH M7 guidelineBhaswat Chakraborty
This document discusses best techniques to control genotoxic impurities according to the ICH M7 guideline. It covers the scope and principles of ICH M7, including risk assessment of potential genotoxic impurities in drug substances and products. It also discusses classification of impurities, acceptable intake levels, control options, and retrospective application of ICH M7 to marketed products. The goal is to limit risk from genotoxic impurities to virtually safe levels through appropriate testing, control, and documentation strategies.
This document discusses ICH guidelines related to impurities in new drug substances and products. It defines key terms like impurity, identified impurity, and potential impurity. It categorizes impurities as organic, inorganic, or residual solvents. The guidelines provide thresholds for identification, qualification, and reporting of impurities. They also classify residual solvents and elemental impurities based on their toxicity, providing permissible daily exposure limits. The guidelines aim to establish qualification of impurities at levels present in early clinical trials and provide a risk-based approach to control impurities.
This document discusses Drug Master Files (DMFs), which contain confidential information about drug components submitted to regulatory agencies like the FDA. It describes the five types of DMFs, including Type II for drug substances, Type III for packaging materials, and Type IV for excipients. The document outlines the roles of DMF holders, applicants, and agencies and review procedures to ensure quality, safety and efficacy of drug products.
This document discusses quality risk management (QRM) and provides an overview of key QRM principles and processes. It defines key risk management terms and describes common risk management tools. The document outlines the general QRM process, which includes risk assessment, control, communication and review. It emphasizes that the level of effort for QRM should be commensurate with the level of risk. Various risk management tools are also described, including failure mode and effects analysis, hazard analysis, hazard operability analysis, and fishbone diagrams.
Q3A(R2) by Anubhav Singh, M.pharm 1st YearAnubhav Singh
This document provides guidance on impurities in new drug substances produced through chemical synthesis. It discusses the classification, identification, control and qualification of impurities. Organic impurities can arise from starting materials, byproducts, intermediates or degradation. Inorganic impurities result from manufacturing processes. The document provides thresholds for identifying and qualifying impurities and recommends reporting impurity levels quantitatively in batch analyses. It also discusses establishing acceptance criteria for impurities based on safety considerations.
ICH Q3AR2 explained - impurities in drug substancesKiran Nivedh
This presentation explains ICH guideline - Q3AR2 in an understandable way by giving examples.
How to impart in the dossier, format for writing impurities in drug substance is given in the book:
1. https://www.scribd.com/book/429190300/Impurities-In-Drug-Substances-ICH-Explained
2. https://www.smashwords.com/books/view/961598
a small book explaining ICH guidelines - impurities in new drug substances with examples
also available in
https://books2search.com/impurities-in-drug-substances-ich-explained-9780463960592
https://www.chapters.indigo.ca/en-ca/books/contributor/author/kiran-nivedh/
Guide technique d’accreditation Analyses microbiologiques des produits et env...Marie Wyon
Ce guide peut aussi être un outil pour les laboratoires mettant en œuvre les normes du domaine agroalimentaire dans un autre domaine d’application (matières fertilisantes et supports de culture notamment).
This document provides information about nitrosamine impurities found in angiotensin II receptor blockers (ARBs) like valsartan, losartan, and irbesartan. It discusses how various nitrosamine impurities like NDMA, NDEA, and NMBA were discovered in 2018-2019 through recalls of ARB medications from multiple manufacturers. It outlines the global investigations and testing methods developed by regulatory agencies like the FDA to detect these genotoxic and carcinogenic impurities and ensure the safety of the drug supply.
The document discusses the International Conference on Harmonization (ICH), which aims to harmonize technical requirements for pharmaceutical registration across Europe, Japan, and the United States. It was established in 1990 as a tripartite effort between regulatory authorities and the research-based pharmaceutical industry. The ICH seeks to reduce unnecessary delay in global drug development by achieving greater harmonization and applying technical guidelines consistently. This will help ensure safe, effective, and high quality new medicines are available more efficiently.
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSBhaumik Bavishi
The document provides guidelines for submitting stability data for drug substances and drug products as part of a registration application. It outlines the objectives, scope, and general principles of stability testing. Guidelines are given for conducting long-term, accelerated, and intermediate stability studies under various storage conditions. Specifications, testing frequency, number of batches, and container closure systems are also addressed. A commitment to continuing stability studies is recommended if the available data does not cover the proposed shelf life period.
This document discusses the requirements for regulatory submissions for marketing authorization in various countries and regions.
It provides an overview of the key documents needed for marketing authorization in India, including application forms, manufacturing licenses, site documents, and product information.
It also summarizes the common ICH CTD format used for submissions to countries like the EU, US, and Japan, as well as the ASEAN CTD format used in Southeast Asian countries. The ASEAN CTD and ICH CTD formats are compared, highlighting similarities and differences in their organization.
Finally, specific documentation requirements are outlined for dossier submissions in countries like Myanmar, Vietnam, and Singapore, focusing on drug substance specifications, analytical methods, and
Impurities in drug substance (ich q3 a)Bhanu Chava
This document discusses guidelines for classifying, reporting, controlling, and qualifying impurities in new drug substances. It defines types of impurities and provides thresholds for reporting, identifying, and qualifying impurities. The key points are:
- Impurities are classified as organic, inorganic, or residual solvents. Organic impurities can arise from starting materials, byproducts, or degradation.
- Identification thresholds determine which impurities must be identified and qualified. Impurities above reporting thresholds must be reported.
- Specifications list individual specified impurities and general limits for unspecified impurities.
- Qualification involves evaluating safety data for impurities at specified levels. Impurities may need further study if usual qualification thresholds
The document discusses guidelines for controlling elemental impurities in pharmaceutical products according to ICH Q3D. It provides information on:
- Common sources of elemental impurities in drug products
- Classification of elements into categories based on their toxicity and likelihood of occurrence
- Methods for establishing permitted daily exposures (PDEs) for elements
- A risk-based approach to assessing and controlling elemental impurities that includes identifying potential sources, evaluating levels compared to PDEs, and documenting control plans
- Options for converting PDEs into concentration limits in drug products or components
The guidelines aim to replace qualitative heavy metal limits with quantitative control of specific elemental impurities shown to have no therapeutic benefit. Manufacturers must
This document provides a summary of the key steps to implement ICH Q3D Guideline for Elemental Impurities:
1. Collect baseline information on potential elemental impurity sources from suppliers.
2. Define the risk assessment strategy to use, such as the component-based Options 1, 2A, 2B or finished-product Option 3.
3. Develop an analytical plan using techniques like ICP-MS to test for elemental impurities.
4. Establish a control strategy where impurities below 30% of the PDE are acceptable.
5. Manage the implementation as a continuous process, reassessing for product or supplier changes.
A comprehensive description of the new requirements introduced by ISO 14971:2019 Application of risk management to medical devices and ISO/TR 24971 Technical Report for the FDA, MDR and IVDR
The document discusses the Paediatric Committee (PDCO) at the European Medicines Agency and its role in regulating medicines for children. It describes how prior to 2007, 50-90% of paediatric medicines lacked testing and evaluation. The Paediatric Regulation of 2007 established the PDCO and incentives like extended exclusivity periods to stimulate research into paediatric medicines. The key tools are Paediatric Investigation Plans which must be approved by the PDCO and outline a medicine's paediatric development. The regulation aims to improve children's health through ethical research while not delaying adult approvals. However, its translation into health benefits requires transparency and coordination between regulators and industry.
The document discusses ICH stability guidelines for pharmaceutical products. It provides an overview of key ICH guidelines including Q1A(R2) on stability testing of new drug substances and products and Q1B on photo stability testing. Q1A(R2) outlines the core stability data package required, including testing conditions, number of batches, and stability commitments. It also defines criteria for significant changes. Q1B covers photo stability testing conditions and study design. The guidelines aim to provide stability information for marketing applications and ensure quality, safety and efficacy over the shelf life of pharmaceutical products.
Best techniques to control Genotoxities and impact of ICH M7 guidelineBhaswat Chakraborty
This document discusses best techniques to control genotoxic impurities according to the ICH M7 guideline. It covers the scope and principles of ICH M7, including risk assessment of potential genotoxic impurities in drug substances and products. It also discusses classification of impurities, acceptable intake levels, control options, and retrospective application of ICH M7 to marketed products. The goal is to limit risk from genotoxic impurities to virtually safe levels through appropriate testing, control, and documentation strategies.
This document discusses ICH guidelines related to impurities in new drug substances and products. It defines key terms like impurity, identified impurity, and potential impurity. It categorizes impurities as organic, inorganic, or residual solvents. The guidelines provide thresholds for identification, qualification, and reporting of impurities. They also classify residual solvents and elemental impurities based on their toxicity, providing permissible daily exposure limits. The guidelines aim to establish qualification of impurities at levels present in early clinical trials and provide a risk-based approach to control impurities.
This document discusses Drug Master Files (DMFs), which contain confidential information about drug components submitted to regulatory agencies like the FDA. It describes the five types of DMFs, including Type II for drug substances, Type III for packaging materials, and Type IV for excipients. The document outlines the roles of DMF holders, applicants, and agencies and review procedures to ensure quality, safety and efficacy of drug products.
This document discusses quality risk management (QRM) and provides an overview of key QRM principles and processes. It defines key risk management terms and describes common risk management tools. The document outlines the general QRM process, which includes risk assessment, control, communication and review. It emphasizes that the level of effort for QRM should be commensurate with the level of risk. Various risk management tools are also described, including failure mode and effects analysis, hazard analysis, hazard operability analysis, and fishbone diagrams.
Q3A(R2) by Anubhav Singh, M.pharm 1st YearAnubhav Singh
This document provides guidance on impurities in new drug substances produced through chemical synthesis. It discusses the classification, identification, control and qualification of impurities. Organic impurities can arise from starting materials, byproducts, intermediates or degradation. Inorganic impurities result from manufacturing processes. The document provides thresholds for identifying and qualifying impurities and recommends reporting impurity levels quantitatively in batch analyses. It also discusses establishing acceptance criteria for impurities based on safety considerations.
ICH Q3AR2 explained - impurities in drug substancesKiran Nivedh
This presentation explains ICH guideline - Q3AR2 in an understandable way by giving examples.
How to impart in the dossier, format for writing impurities in drug substance is given in the book:
1. https://www.scribd.com/book/429190300/Impurities-In-Drug-Substances-ICH-Explained
2. https://www.smashwords.com/books/view/961598
a small book explaining ICH guidelines - impurities in new drug substances with examples
also available in
https://books2search.com/impurities-in-drug-substances-ich-explained-9780463960592
https://www.chapters.indigo.ca/en-ca/books/contributor/author/kiran-nivedh/
Guide technique d’accreditation Analyses microbiologiques des produits et env...Marie Wyon
Ce guide peut aussi être un outil pour les laboratoires mettant en œuvre les normes du domaine agroalimentaire dans un autre domaine d’application (matières fertilisantes et supports de culture notamment).
Laboratoire du futur II - les enjeux, perspectives et valeur ajoutée dans les...Yvon Gervaise
Cours conférence du 1er février 2018 (partie II) de Yvon Gervaise, à l'Université des Sciences de Rouen.
Laboratoire du futur, perspectives et valeur ajoutée dans l'évaluation des produits des filières polymères, chimie et matériaux
les tests en Recherche et Developpement industriel , diversité des applications Panorama evolution des Methodes de dosage quantitatif des P.E; (Perturbateurs Endocriniens ) Communication de Yvon Gervaise animateur du GT laboratoire du futur à la SECF ( societe des Experts Chimistes de France ) au Colloque 2020 EHESP - ARET ( Ecole Hautes Etudes en Sante Publique - Association Recherche en Toxicologie) 21/10/2020
Recycling 2015 conference by Yvon Gervaise held in Metz on March 18thYvon Gervaise
Recycling 2015 conference by Yvon Gervaise held in Metz on March 18th : SGS MULTILAB has recently implemented an innovating tool baptized : @wastevalorisationmanager designed to establish reports containing all legal and mandatory information about waste characterization in order to facilitate their repurposing.
Atelier spot « La vérification ETV des performances de votre innovation : un ...PEXE
Présentation de l'atelier spot « La vérification ETV des performances de votre innovation : un atout pour sa commercialisation » animé par l'Ademe dans le cadre de la 8ème édition du Forum national des éco-entreprises qui a eu lieu le 30 mars 2017 au Ministère de l'économie
L’Agence de l’Environnement et de la Maîtrise de l’Energie (ADEME) participe à la mise en œuvre des politiques publiques dans les domaines de l’environnement, de l’énergie et du développement durable.
L'analyse multiparamétrique, promesses pour la qualité, l'authentification et...Yvon Gervaise
Conférence à Rennes le 15 juin 2016 par Yvon Gervaise à Food Industry Meetings : Rendez-vous des industries agro-alimentaires.
Transparence, qualité des produits, à industrie agro-alimentaire du futur, le laboratoire du futur.
Robotisation et analyses multiparamétriques
déchets: valorisation, élimination et caractérisation des déchets.
Nouveaux processus de caractérisation pour l'optimisation des filières de valorisation matière ou énergie des produits en fin de cycle de vie.
analyse chimique et écotoxicologique et établissement des critères de classification et de dangerositié.
Introduction au développement chimique pharmaceutiqueDiolez Christian
Partie du cours de Mr Christian Diolez Expert consultant en chimie organique et développement chimique pharmaceutique donné à l'école de chimie de Rennes
Mots clés: Chimie, développement chimique, cours, principe actif, chimie organique, sécurité, cGMP, ICH,
Augmentez la disponibilité de vos matériels grâce aux analyse de fluides (huiles, graisses, fluides diélectriques, liquides de refroidissement, ...). Découvrez toutes les solutions d'analyses de fluides et lubrifiants proposées par IESPM GROUP pour le secteur de l'industrie chimique
04 12 INSA Spectrométrie, chromatographie, écotoxicologie au service des écot...Yvon Gervaise
Éco-matériaux, définition. Analyse du cycle de vie et enjeux, caractérisation à SGS Multilab Rouen
Applications et exemples illustrés dans les secteurs du bâtiment, de l’automobile de la plasturgie…
Échéance de la nouvelle réglementation
Nouveaux protocoles développés à SGS Multilab Rouen
Analyse et caractérisation des C.O.V. aux différents stades du cycle de vie des produits et des matériaux
Similaire à Implémentation de la guideline ICH Q3D (20)
2. IDENTIFIERCOLLECTEREVALUERANALYSERCONCLURE
Le laboratoire GIFRER-BARBEZAT
En quelques points :
o 14 hectares
o Site classé SEVESO 2 seuil haut
o 5 ateliers de fabrication
o Unidoses (300 millions d’unidoses à l’année)
o Inflammables (Ether, Alcool modifié, Gluconate de Chlorhexidine)
o Liniment oléo-calcaire
o Eau oxygénée
o Extraction végétale (catalogue de 250 plantes)
o 43 721 000 euros de CA en 2016
3. ICH Q3D : introduction
Objectif : évaluer le taux d’impuretés élémentaires des produits finis disposant d’une
autorisation de mise sur le marché. (étape 4 de l’ICH Q3D)
▪ Causes : matières premières, procédés de fabrication (réactifs organométalliques,
catalyseurs métalliques, équipements de fabrication), et conditionnements primaires.
▪ Méthodes d’analyses : spectrométrie de masse à plasma (IPC-MS) ou
spectrométrie d’émission optique (ICP-AES ou ICP-OES).
Portée de la réglementation :
▪ Les nouveaux médicaments ou formulations qui contiennent des substances
pharmaceutiques existantes sur le marché.
▪ À partir de décembre 2017, tous les produits disposant d’une AMM sur le marché
devront être en conformité.
IDENTIFIERCOLLECTEREVALUERANALYSERCONCLURE
1
4. ICH Q3D : identifier les causes
Ingrédients
Matières
premières
Catalyseurs
métalliques
Réactifs
organométalliques
Procédé de fabrication
Corrosion
Type de transformation
physique
Utilitaires
(eau/air/azote)
Equipements Conditionnement primaire
Impuretés élémentaires
dans le produit fini
Conditionnements
primaires
Composants
Procédés de
fabrication
Formulation
Forme galénique
Dose journalière
maximale
Voie
d’administration
Variation de
pH
Chauffe
Temps de
contact
Matériaux
Conditions
de stockage
*: matières premières
articles de conditionnement
IDENTIFIERCOLLECTEREVALUERANALYSERCONCLURE
2
5. IDENTIFICATION
Nom du produit et code
CIS
Informations sur le
fabricant
Quantité par boîte
Posologie
Dose journalière
maximale
Voie d’administration
Forme galénique
Formulation
(proportions)
FABRICATION
Equipements
Catalyseurs métalliques
Réactifs
organométalliques
Variation de pH
Chauffe
Temps de contact par
équipements
CONDITIONNEMENT
Matériaux
Etat physique du produit
Conditions de stockage
Produits finis
ICH Q3D : collecter les informations
Certificats
matériaux
Etudes
d’extractibles
et relargables
Spécifications
Dossier de lot
Dossier
d’AMM
IDENTIFIER
COLLECTER
EVALUERANALYSERCONCLURE
3
6. IDENTIFICATION
Désignations des
substances actives et
excipients
Informations
fournisseurs / fabricants
Certification : Ph. Eur,
Ph. Fr…
Origines : plante,
animale, synthétique,
minéral
Résidus de catalyse,
impuretés métalliques
élémentaires
Environnement de
production
Formulation
(proportions)
CONDITIONNEMENT
Matériau
Etat physique du produit
Conditions de stockage
Matières premières
ICH Q3D : collecter les informations
Certificats
d’analyses
ICH Q3D
Méthode HACCP
FABRICATION
Catalyseurs métalliques
Réactifs
organométalliques
Corrosion /
Maintenance
Cotation
Analyse de
risque
Le produit fini
Cotation
Spécifications
Dossier de lot
Dossier
d’AMM
IDENTIFIER
COLLECTER
EVALUERANALYSERCONCLURE
6
4
7. ICH Q3D : collecter les informations
Questionnaires :
Questionnaire fabricants/façonniers
Questionnaire fournisseurs de matières premières
Questionnaire fournisseurs d’articles de conditionnements
Annexes :
7
IDENTIFIER
COLLECTER
EVALUERANALYSERCONCLURE
5
Feuille de calcul pour collecter les
résultats analytiques
8. ICH Q3D : collecter les informations
Annexe : feuille de calcul ICH Q3D
IDENTIFIER
COLLECTER
EVALUERANALYSERCONCLURE
6
9. ICH Q3D : évaluer la contamination
IDENTIFIERCOLLECTEREVALUERANALYSERCONCLURE
7
CONDITIONNEMENTS PRIMAIRES
10. ICH Q3D : évaluer la contamination
IDENTIFIERCOLLECTEREVALUERANALYSERCONCLURE
8
11. ICH Q3D : analyser le produit fini
Etat actuel du projet :
▪ Analyses ICP-MS sous traitées
▪ Résultats courant août
Méthode de calcul : option 3, produit fini
Exemple : Compralgyl 400mg/20mg
Option 3 : limite de concentrations admissibles pour le produit fini
Composant
Dose
journalière (g)
Concentration maximale admissible (µg/g)
Cd Pb As Hg Co V Ni Tl Au Pd Ir Os Rh Ru Se Ag Pt Li Sb Ba Mo Cu Sn Cr
1 1 1 1 2a 2a 2a 2b 2b 2b 2b 2b 2b 2b 2b 2b 2b 3 3 3 3 3 3 3
Produit fini 3 2 2 5 10 17 33 67 3 33 33 33 33 33 33 50 50 33 183 400 467 1000 1000 2000 3667
EJA (µg) 5 5 15 30 50 100 200 8 100 100 100 100 100 100 150 150 100 550 1200 1400 3000 3000 6000 11000
Moyenne des concentrations
analysées (µg/g)
Note : avec les certificats d’analyses en métaux lourds des matières premières et avec l’option de calcul 2b nous
pouvons estimer la limite de concentration pour chaque matière première en prenant en compte la dose
maximale journalière admissible de produit fini.
11
IDENTIFIERCOLLECTEREVALUER
ANALYSER
CONCLURE
9
12. ICH Q3D : conclusion 10
Niveaux des IE estimés Actions Stratégie de contrôle
IE non présente documenter aucune action requise
IE < 30% EJA pas d'action supplémentaire à mettre en œuvre contrôle existants adéquats
30% EJA < IE < EJA
définir des contrôles supplémentaires pour maîtriser
ou
définir des contrôles en amont et évaluer l'impact sur
les IE
spécification sur le médicament
ou les composants
possibilité de réaliser des
contrôles périodiques
IE > EJA
définir des contrôles supplémentaires pour diminuer
ou
évaluer la sécurité du patient et établir un rationnel
pour justifier des teneurs plus élevées en IE
spécification sur le médicament
ou les composants
définir des contrôles en amont
et évaluer l'impact sur les IE
IDENTIFIERCOLLECTEREVALUERANALYSERCONCLURE